Decera Clinical Education Infectious Disease Podcast

In this episode, Part 1 of an 4-part series, Dr. Joseph J. Eron, Jr., Professor Chloe Orkin, and Dr. Paul E. Sax, discuss key health challenges faced by aging patients with HIV and answer clinicians’ questions on HIV treatment considerations and on prevention, screening, and treatment of common age-related comorbidities.Presenters:Joseph J. Eron, Jr., MDProfessor of Medicine and EpidemiologyUniversity of North Carolina School of MedicineDirector, AIDS Clinical Trials UnitUniversity of North CarolinaChapel Hill, North Carolina Chloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomPaul E. Sax, MDClinical Director HIV Program and Division of Infectious DiseasesBrigham and Women’s HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME/CE/CPE-certified program supported by educational grants from Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and ViiV Healthcare.Link to full program:https://bit.ly/32JD145 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Stefan Zeuzem discusses results from key viral hepatitis studies reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver, including important findings from the following reports:Update on global progress toward HCV elimination goalsSToP-C: HCV treatment-as-prevention in Australian prisonsSHARED cohort: correlates of treatment failure with GLE/PIB or SOF/VEL/VOXTrio Health: retreating HCV with GLE/PIB or SOF/VEL/VOX after DAA failureStop-NUC: discontinuation of long-term nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic HBV infectionHigh-dose bulevirtide for chronic HBV/HDV coinfectionSummary of select agents under early-phase investigation for HBV treatmentPresenter:Stefan Zeuzem, MDProfessor of Medicine Chief, Department of Medicine I JW Goethe University Hospital Frankfurt, GermanyContent based on a CME program supported by an independent educational grant from Gilead Sciences.Link to full program:https://bit.ly/33nkRUI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Part 5 of an ongoing 12-part COVID-19 series, David Heymann, BA, MD, DTM&H, provides a brief update on the epidemiology of SARS-CoV-2 and evidence-based interventions for reducing transmission,. After the update, Professor Heymann answers critical clinician questions on COVID-19 transmission and mitigation.Presenter:David Heymann, BA, MD, DTM&HProfessor, Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine; andDistinguished Fellow, Centre on Universal Health at Chatham House, LondonLondon, United KingdomContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program: https://bit.ly/3eDoJF0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Sherer discusses results from key studies reported at the International AIDS Society’s 2020 Virtual COVID-19 Conference, including studies evaluating characteristics and predictors of COVID-19 mortality, factors associated with remdesivir clinical outcomes, the effect of hydroxychloroquine coadministration on remdesivir safety and efficacy, the effect of race/ethnicity on clinical outcomes with remdesivir, and sofosbuvir/daclatasvir plus lopinavir/ritonavir for the treatment of severe COVID-19.Presenter:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineUniversity of ChicagoChicago, IllinoisContent based on a CME program supported by an independent educational grant from Gilead Sciences.Link to full program: https://bit.ly/2Q7GDp2 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Orkin discusses results from key studies reported at AIDS 2020: Virtual, with new data on the following hot topics: current ART in principal populations, including older patients and women who become pregnant; metabolic outcomes during ART; HIV and COVID-19; investigational ART strategies; and HIV prevention. The overview includes: The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDFA pooled analysis of randomized trials evaluating a switch to BIC/FTC/TAF in patients 65 years of age or older with virologic suppression on their current ARTA Kaiser Permanente study of BMI changes over time following ART initiation An analysis of the longitudinal prospective OPERA cohort that assessed weight change with switch from TDF to TAFMetabolic changes with switch from 3- or 4-drug TAF-based ART to 2-drug DTG/3TC in the TANGO studyUpdated findings from the Tsepamo birth surveillance study in Botswana evaluating the prevalence of neural tube defects by antiretroviral exposure during conception/pregnancyA retrospective study of COVID-19 in people with HIV presenting at 5 New York City Emergency Departments from March 2 to April 15, 2020An analysis of protocol-defined virologic failure in the P011 study comparing islatravir plus DOR vs DOR/3TC/TDF in treatment-naive adultsA study evaluating the lenacapavir pharmacokinetic profileResults from the HPTN 083 trial investigating the efficacy and safety of long-acting injectable cabotegravir vs daily oral TDF/FTC for PrEP in MSM and TGWPresenter:Chloe Orkin, MBChB, FRCP, MDProfessor of HIV Queen Mary, University of LondonConsultant PhysicianLead for HIV Research Barts Health NHS TrustThe Royal London HospitalLondon, United KingdomContent based on a CME program supported by independent educational grants from Gilead Sciences, Merck Sharp & Dohme Corp., and ViiV Healthcare.Link to full program: https://bit.ly/33YRz0t Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Part 4 of an ongoing 12-part COVID-19 series, Vikramjit Mukherjee, MD, provides a brief update on the latest incidence trends and a concise summary of updates to the US National Institutes of Health and the Infectious Diseases Society of America recommendations for managing COVID-19. After the update, Dr. Mukherjee answers critical clinician questions on COVID-19 transmission, diagnosis, and management.Presenter:Vikramjit Mukherjee, MDDirector, Medical Intensive Care UnitBellevue HospitalAssistant ProfessorDivision of Pulmonary, Critical Care, and Sleep MedicineNYU School of MedicineNew York, New YorkContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program:https://bit.ly/3eDoJF0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Christian B. Ramers, MD, MPH, and Sandra Springer, MD, discuss current evidence supporting the need for integrated addiction and infectious disease care and review the wide array of benefits that can be realized when these services are provided in tandem, ideally at the same clinic and by the same healthcare provider.Presenters:Christian B. Ramers, MD, MPHAssociate Clinical ProfessorDivision of Infectious DiseasesDepartment of MedicineUC San Diego School of MedicineLa Jolla, CaliforniaChief, Population HealthDirector, Graduate Medical EducationFamily Health Centers of San DiegoSan Diego, CaliforniaSandra Springer, MD Associate Professor of MedicineDivision of Infectious DiseaseDepartment of Internal MedicineYale School of MedicineNew Haven, ConnecticutAttending PhysicianSection of Infectious DiseaseDepartment of Internal MedicineVeterans Administration Connecticut Healthcare ServicesWest Haven, ConnecticutContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program:https://bit.ly/2Zcdoqw Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Part 3 of an ongoing 12-part COVID-19 series, Sharon Lewin, AO, FRACP, PhD, FAAHMS, provides a brief update on the latest incidence trends and a concise guide to the management of mild and moderate disease. After the update, Dr. Lewin answers critical clinician questions on COVID-19 transmission, diagnosis, and management.Presenter:Sharon Lewin, AO, FRACP, PhD, FAAHMSDirectorThe Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesUniversity of MelbourneConsultant Infectious Disease PhysicianAlfred Hospital and Royal Melbourne HospitalMelbourne, AustraliaContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program: https://bit.ly/3eDoJF0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Part 2 of an ongoing 12-part COVID-19 series, Jens D. Lundgren, MD, DMSc, provides a brief update on the latest incidence trends, a concise guide to viral diagnostic testing, and new data on investigational treatment options. After the update, Dr. Lundgren answers critical clinician questions on COVID-19 transmission, diagnosis, and management.Presenter:Jens D. Lundgren, MD, DMScProfessorDirector, Centre of Excellence for Health, Immunity and Infection (CHIP)RigshospitalUniversity of CopenhagenCopenhagen, DenmarkContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program: https://bit.ly/3eDoJF0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Kuritzkes and Dr. Ramers provide a case-based discussion addressing several age-related comorbidities among people with HIV, including bone loss, renal impairment, cardiovascular disease, mental health disorders, and neurocognitive disorders. Their discussion includes analysis of key data from the following HIV studies: DRIVE-AHEAD: Neuropsychiatric Events With First-line DOR/3TC/TDF vs EFV/FTC/TDFTANGO: Renal and Bone Changes With Switch to DTG/3TCSWORD-1/2: Renal and Bone Changes With Switch to DTG + RPVStudy 1961: Quantitative Proteinuria by Baseline Regimen With Switch to BIC/FTC/TAF in WomenStudies 1216 and 1160: Bone Changes With Switch to RPV/FTC/TAFNA-ACCORD: Increased MI Risk Among PWHD:A:D: Increased CVD Risk With Boosted PIsDanish HIV Cohort Study: Impact of Smoking on MI RiskD:A:D: Impact of Smoking on MI RiskIn addition, Dr. Kuritzkes and Dr. Ramers discuss relevant data and practical strategies for smoking cessation among people with HIV as well as risk factors, pathogenesis, and challenges in the clinical management of HIV-associated neurocognitive disorders.Presenters:Daniel R. Kuritzkes, MDChief, Division of Infectious DiseasesBrigham and Women’s HospitalHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolBoston, MassachusettsChristian B. Ramers, MD, MPHAssociate Clinical ProfessorDivision of Infectious DiseasesDepartment of MedicineUC San Diego School of MedicineLa Jolla, CaliforniaChief, Population HealthDirector, Graduate Medical EducationFamily Health Centers of San DiegoSan Diego, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to downloadable slideset associated with this podcast: https://bit.ly/2MuoEHFLink to full program: https://bit.ly/3cFzy8o Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Part 1 of an ongoing 12-part COVID-19 series, Vikramjit Mukherjee, MD, provides a brief update on the latest incidence trends, the role of serology in disease assessment, and newly published data from the ACTT-1 trial comparing remdesivir vs placebo for severe COVID-19 treatment. After the update, Dr. Mukherjee answers critical clinician questions on COVID-19 transmission, diagnosis, and management.Presenter:Vikramjit Mukherjee, MDDirector, Medical Intensive Care UnitBellevue HospitalAssistant ProfessorDivision of Pulmonary, Critical Care, and Sleep MedicineNYU School of MedicineNew York, New YorkContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program: https://bit.ly/3eDoJF0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Gandhi discusses topline results from several studies investigating weight gain and metabolic outcomes with different antiretroviral therapy (ART) regimens among patients with HIV, including lipid level changes, cardiovascular disease risk, diabetes risk, and metabolic syndrome risk. The overview will include analyses from: The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF, including an examination of the influence of CYP2B6 polymorphisms on weight change during EFV-based therapyThe NA-ACCORD studyEvaluating patients with virologic suppression who switched from non–integrase inhibitor (INSTI)–based regimens to INSTI-based regimensInvestigating the impact of initial ART regimen class on diabetes mellitus incidenceA study investigating the association between resting metabolic rate, oxygen consumption, and dietary intake changes and body weight/composition changes following ART initiationA study evaluating differences in postpartum weight change with DTG-based vs EFV-based ARTIn addition, Dr. Gandhi reviews new information on biomedical prevention of HIV infection, including results from several preclinical trials, a study investigating real-time urine-based testing for tenofovir levels, and the latest safety data from the phase III DISCOVER trial comparing FTC/TDF vs FTC/TAF for daily oral HIV pre-exposure prophylaxis (PrEP) among cis-gender men who have sex with men (MSM) and transgender women.Presenter:Monica Gandhi, MD, MPH Professor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineUniversity of California, San FranciscoMedical DirectorWard 86 HIV ClinicSan Francisco General HospitalSan Francisco, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.Link to full program: https://bit.ly/3bBjeoD Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.